Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus (Q38417643)
Jump to navigation
Jump to search
scientific article published on 26 February 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus |
scientific article published on 26 February 2010 |
Statements
1 reference
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus (English)
1 reference
Warner K Huh
1 reference
Michael W Sill
1 reference
Kathleen M Darcy
1 reference
Kevin M Elias
1 reference
James S Hoffman
1 reference
John F Boggess
1 reference
Ronald D Alvarez
1 reference
Harry J Long
1 reference
David M O'Malley
1 reference
Michael J Birrer
1 reference
26 February 2010
1 reference
1 reference
2 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference